On November 15, 2017, the U.S. Food and Drug Administration (FDA) granted marketing approval for the first prescription device intended to treat physical symptoms of opioid withdrawal during a supervised addiction treatment program. The goal is to help users manage the acute withdrawal symptoms so that they continue with treatment, including the transition to medication assisted treatment (MAT). The device, created by Innovative Health Solutions, Inc., is called the Bridge Neurostimulation System (NSS-2 BRIDGE).
The small NSS-2 BRIDGE device is an electrical nerve field stimulator that is attached behind the ear with adhesives; the electrodes are attached . . .